Hypertrophic Cardiomyopathy (HCM)
Vaccines: 2023 Year in Review
Eyecare
Urothelial Carcinoma
Women's Health
Hemophilia
Heart Failure
Vaccines
Neonatal Care
NSCLC
Type II Inflammation
Substance Use Disorder
Gene Therapy
Lung Cancer
Spinal Muscular Atrophy
HIV
Post-Acute Care
Liver Disease
Pulmonary Arterial Hypertension
Biologics
Asthma
Atrial Fibrillation
Type I Diabetes
RSV
COVID-19
Cardiovascular Diseases
Breast Cancer
Prescription Digital Therapeutics
Reproductive Health
The Improving Patient Access Podcast
Blood Cancer
Ulcerative Colitis
Respiratory Conditions
Multiple Sclerosis
Digital Health
Population Health
Sleep Disorders
Biosimilars
Plaque Psoriasis
Leukemia and Lymphoma
Oncology
Pediatrics
Urology
Obstetrics-Gynecology & Women's Health
Opioids
Solid Tumors
Autoimmune Diseases
Dermatology
Diabetes
Mental Health

Secondary Progressive Multiple Sclerosis: Patient Impact and Coverage Implications for New Therapies : Episode 10

A Labeling Indication of SPMS Can Treat More Patients

Name: A Labeling Indication of SPMS Can Treat More Patients
Uploaded: 2020-12-16T20:00:00.000Z
Description: Fred Lublin, MD, says a new labeling indication of Secondary Progressive Multiple Sclerosis broadens whom you can treat. He adds this will be very helpful to patients because it will treat groups that are progressing slowly without agents of activity.

December 16, 2020

Video

Fred Lublin, MD, says a new labeling indication of Secondary Progressive Multiple Sclerosis broadens whom you can treat. He adds this will be very helpful to patients because it will treat groups that are progressing slowly without agents of activity.